FTC Renews Attacks on ‘Improper’ Drug-Device Patent Listings (1)

Seventeen brand-name drugs including Teva’s Qvar inhalers and Viatris’ EpiPen are the focus of the Federal Trade Commission’s third wave of challenges to more than 200 patents it says are improperly listed in the FDA’s Orange Book.

The FTC sent warning letters May 20 to seven companies targeting listings its Wednesday press release said remain in place despite earlier disputes and a federal appeals court ruling clarifying that many device-related patents don’t qualify to be listed on the Food and Drug Administration’s registry of approved drugs.

Companies have 30 days to delist the patents or certify under penalty of perjury ...